Forbion Portfolio Company, AM-Pharma raises €116m
Posted on July 16, 2019 in Forbion, Forbion highlight, Highlights
Forbion Portfolio Company, AM-Pharma raises €116m to conduct Pivotal Phase III Trial of recAP in acute kidney injury.